Table 2. Proportion of subjects with different HLA types.
| All SP | Elite (n = 42) | Virologic (n = 63) | Non-virologic (n = 30) | P valueA | All SP (n = 135) | Primo(n = 455) | P valueB |
|---|---|---|---|---|---|---|---|
| Num of protective alleles, n (%) | 0.525 | <0.001 | |||||
| 0 | 13 (31.0) | 22 (34.9) | 15 (50.0) | 50 (37.0) | 261 (57.4) | ||
| 1 | 22 (52.4) | 33 (52.4) | 12 (40.0) | 67 (49.6) | 180 (39.6) | ||
| 2 | 7 (16.7) | 8 (12.7) | 3 (10.0) | 18 (13.3) | 14 (3.1) | ||
| With protective alleles, n (%) | 0.229 | <0.001 | |||||
| No | 13 (31.0) | 22 (34.9) | 15 (50.0) | 50 (37.0) | 261 (57.4) | ||
| Yes | 29 (69.0) | 41 (65.1) | 15 (50.0) | 85 (63.0) | 194 (42.6) | ||
| HLA type, n (%) | |||||||
| B*13 | 2 (4.8) | 5 (7.9) | 3 (10.0) | 0.702 | 10 (7.4) | 8 (1.8) | 0.001 |
| B*14 | 3 (7.1) | 10 (15.9) | 6 (20.0) | 0.258 | 19 (14.1) | 43 (9.5) | 0.124 |
| B*27 | 12 (28.6) | 11 (17.5) | 1 (3.3) | 0.022 | 24 (17.8) | 37 (8.1) | 0.001 |
| B*38 | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0.533 | 1 (0.7) | 18 (4.0) | 0.063 |
| B*51 | 4 (9.5) | 5 (7.9) | 1 (3.3) | 0.640 | 10 (7.4) | 65 (14.3) | 0.035 |
| B*57 | 11 (26.2) | 15 (23.8) | 4 (13.3) | 0.397 | 30 (22.2) | 25 (5.5) | <0.001 |
| B*58 | 3 (7.1) | 2 (3.2) | 2 (6.7) | 0.604 | 7 (5.2) | 12 (2.6) | 0.141 |
| B*81 | 0 (0.0) | 1 (1.6) | 1 (3.3) | 0.492 | 2 (1.5) | 0 (0.0) | 0.052 |
| 3DL1*h/*y + B*57 | 3 (7.9) | 8 (14.0) | 3 (10.3) | 0.717 | 14 (11.3) | 9 (2.0) | <0.001 |
Genotype data missing for 11 SP subjects and 35 subjects in the Primo cohort
Protective alleles - among HLA-B*13, B*14, B*27, B*38, B*51, B*57, B*58 and B*81
P values are based on Fisher’s exact test/Chi square test as appropriate
AComparison between the SP.
BComparison between all SP and Primo.